Analysis of bacterial biofilms using NMR-based metabolomics

Future Medicinal Chemistry

Volumn 4, Issue 10, 2012, Pages 1273-1306

  Zhang, Bo ^a   Powers, Robert ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIGMA FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIUM CULTURE; BIOFILM; BIOINFORMATICS; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMOMETRICS; CLUSTER ANALYSIS; COMPUTER PROGRAM; DRUG DEVELOPMENT; GENOMICS; HETERONUCLEAR SINGLE QUANTUM COHERENCE; METABOLISM; METABOLOME; METABOLOMICS; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; REVIEW;

BACTERIA; BIOFILMS; CLUSTER ANALYSIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOME; METABOLOMICS; PLANKTON; PRINCIPAL COMPONENT ANALYSIS; PSEUDOMONAS AERUGINOSA;

EID: 84863954678     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.59     Document Type: Review

References (274)

1. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu. Rev. Microbiol. 54, 49-79 (2000).
2. Costerton JW. Overview of microbial biofilms. J. Ind. Microbiol. 15(3), 137-140 (1995).
3. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu. Rev. Microbiol. 49, 711-745 (1995).
4. Simões LC, Simões M, Vieira MJ. Biofilm interactions between distinct bacterial genera isolated from drinking water. Appl. Environ. Microbiol. 73(19), 9 (2007).
5. Nadell CD, Xavier JB, Foster KR. The sociobiology of biofilms. FEMS Microbiol. Rev. 33(1), 206-224 (2009).
6. Hiroyuki K. Biofilm disease. Its clinical manifestation and therapeutic possibilities of macrolides. Am. J. Med. 99(6, Suppl. 1), 26s-30s (1995).
7. Klaus-Joerger T, Joerger R, Olsson E, Granqvist C-G. Bacteria as workers in the living factory. Metal-Accumulating bacteria and their potential for materials science. Trends Biotechnol. 19(1), 15-20 (2001).
8. Van Loosdrecht MCM, Eikelboom D, Gjaltema A, Mulder A, Tijhuis L, Heijnen JJ. Biofilm structures. Water Sci. Technol. 32(8), 35-43 (1995).
9. Lens P, Moran AP, Mahony T, Stoodley P, O'flaherty V. Biofilms in medicine, industry and environmental biotechnology. Characteristics, analysis and control. Mater. Corros. 56(1), 55 (2005).
10. Hughes JM. Addressing emerging infectious disease threats-Accomplishments and future plans. Emerg. Infect. Dis. 4(3), 360-361 (1998).
11. Gannon JC. The global infectious disease threat and its implications for the United States. Prot. Sci. 79(4), 1-63 (2000).
12. Lewis K. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45(4), 999-1007 (2001).
13. Davies D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2(2), 114-122 (2003).
14. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 325(5944), 1089-1093 (2009).
15. Kennedy AD, Otto M, Braughton KR et al. Epidemic community-Associated methicillin-Resistant Staphylococcus aureus. Recent clonal expansion and diversification. Proc. Natl Acad. Sci. USA 105(4), S1327-S1332 (2008).
16. Kohn WG, Collins AS, Cleveland JL, Harte JA, Eklund KJ, Malvitz DM. Guidelines for infection control in dental health-Care settings-2003. MMWR Recomm. Rep. 52(RR-17), 1-61 (2003).
17. Hetrick EM, Schoenfisch MH. Reducing implant-Related infections. Active release strategies. Chem. Soc. Rev. 35(9), 780-789 (2006).
18. Parsek MR, Singh PK. Bacterial biofilms. An emerging link to disease pathogenesis. Annu. Rev. Microbiol. 57, 677-701 (2003).
19. Savage DC. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 31, 107-133 (1977).
20. Marsh PD, Moter A, Devine DA. Dental plaque biofilms. communities, conflict and control. Periodontology 2000 55(1), 16-35 (2011).
21. Nicolle LE. Catheter-Related urinary tract infection. Drugs Aging 22(8), 627-639 (2005).
22. Campoccia D, Montanaro L, Baldassarri L, An YH, Arciola CR. Antibiotic resistance in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates from implant orthopedic infections. Int. J. Artif. Organs 28(11), 1186-1191 (2005).
23. Nishimura S, Tsurumoto T, Yonekura A, Adachi K, Shindo H. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases. J. Orthop. Sci. 11(1), 46-50 (2006).
24. Laplante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-Resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob. Agents Chemother. 53(9), 3880-3886 (2009).
25. Padera RF. Infection in ventricular assist devices. The role of biofilm. Cardiovasc. Pathol. 15(5), 264-270 (2006).
26. Vadyvaloo V, Otto M. Molecular genetics of Staphylococcus epidermidis biofilms on indwelling medical devices. Int. J. Artif. Organs. 28(11), 1069-1078 (2005).
27. Sohail MR, Uslan DZ, Khan AH et al. Management and outcome of permanent pacemaker and implantable cardioverter-Defibrillator infections. J. Am. Coll. Cardiol. 49(18), 1851-1859 (2007).
28. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent. Cure with prolonged/high-Dose daptomycin without toxicity. Heart Lung 35(3), 207-211 (2006).
29. Peacock SJ, Curtis N, Berendt AR, Bowler IC, Winearls CG, Maxwell P. Outcome following haemodialysis catheter-Related Staphylococcus aureus bacteraemia. J. Hosp. Infect. 41(3), 223-228 (1999).
30. Knudsen AM, Rosdahl VT, Espersen F, Frimodt-Moller N, Skinhoj P, Bentzon MW. Catheter-Related Staphylococcus aureus infections. J. Hosp. Infect. 23(2), 123-131 (1993).
31. Ghanem GA, Boktour M, Warneke C et al. Catheter-Related Staphylococcus aureus bacteremia in cancer patients. High rate of complications with therapeutic implications. Medicine 86(1), 54-60 (2007).
32. Hall RE, Ash AS, Ghali WA, Moskowitz MA. Hospital cost of complications associated with coronary artery bypass graft surgery. Am. J. Cardiol. 79(12), 1680-1682 (1997).
33. Simon D, Fischer S, Grossman A et al. Left ventricular assist device-Related infection. treatment and outcome. Clin. Infect. Dis. 40(8), 1108-1115 (2005).
34. Holman WL, Rayburn BK, Mcgiffin DC et al. Infection in ventricular assist devices. Prevention and treatment. Ann. Thorac. Surg. 75(6 Suppl.), S48-S57 (2003).
35. Herrmann M, Weyand M, Greshake B et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 95(4), 814-817 (1997).
36. Fischer SA, Trenholme GM, Costanzo MR, Piccione W. Infectious complications in left ventricular assist device recipients. Clin. Infect. Dis. 24(1), 18-23 (1997).
37. Holman WL, Park SJ, Long JW et al. Infection in permanent circulatory support experience from the rematch trial. J. Heart Lung Transplant. 23(12), 1359-1365 (2004).
38. Mohamed JA, Huang DB. Biofilm formation by enterococci. J. Med. Microbiol. 56(Pt 12), 1581-1588 (2007).
39. Olmstead S, Meiss D, Ralston J. Life on the edge. The clinical implications of gastrointestinal biofilm. Newsletter Spring 2003 (2003).
40. O'Toole GA. To build a biofilm. J. Bacteriol. 185(9), 2687-2689 (2003).
41. Stewart P, Franklin M. Physiological heterogeneity in biofilms. Nat. Rev. Microbiol. 6(3), 199-210 (2008).
42. Davey ME, O'Toole GA. Microbial biofilms. from ecology to molecular genetics. Microbiol. Mol. Biol. Rev. 64(4), 847-867 (2000).
43. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms. From the natural environment to infectious diseases. Nat. Rev. Microbiol. 2(2), 95-108 (2004).
44. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu. Rev. Microbiol. 56, 187-209 (2002).
45. Lawrence JR, Korber DR, Hoyle BD, Costerton JW, Caldwell DE. Optical sectioning of microbial biofilms. J. Bacteriol. 173(20), 6558-6567 (1991).
46. Wickham JR, Rice CV. Solid-state NMR studies of bacterial lipoteichoic acid adsorption on different surfaces. Solid State Nucl. Magn. Reson. 34(3), 154-161 (2008).
47. Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol. 13(1), 7-10 (2005).
48. Yasuda H. Bacterial biofilms and infectious diseases. Trends Glycosci. Glycotechnol. 8(44), 409-417 (1996).
49. O'Toole GA, Gibbs KA, Hager PW, Phibbs PV Jr, Kolter R. The global carbon metabolism regulator Crc is a component of a signal transduction pathway required for biofilm development by Pseudomonas aeruginosa. J. Bacteriol. 182(2), 425-431 (2000).
50. Stanley PM. Factors affecting the irreversible attachment of Pseudomonas aeruginosa to stainless steel. Can. J. Microbiol. 29(11), 1493-1499 (1983).
51. Watnick PI, Kolter R. Steps in the development of a Vibrio cholerae El Tor biofilm. Mol. Microbiol. 34(3), 586-595 (1999).
52. Maira-Litran T, Kropec A, Abeygunawardana C et al. Immunochemical properties of the Staphylococcal poly-N-Acetylglucosamine surface polysaccharide. Infect. Immun. 70(8), 4433-4440 (2002).
53. Mack D, Fischer W, Krokotsch A et al. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan. purification and structural analysis. J. Bacteriol. 178(1), 175-183 (1996).
54. Van Loosdrecht MC, Lyklema J, Norde W, Zehnder AJ. Influence of interfaces on microbial activity. Microbiol. Rev. 54(1), 75-87 (1990).
55. Debeer D, Stoodley P, Roe FL, Lewandowski Z. Effects of biofilm structures on oxygen distribution and mass transpoct. Biotech. Bioeng. 43(11), 1131-1138 (1994).
56. Lawrence JR, Neu TR. Confocal laser scanning microscopy for analysis of microbial biofilms. Methods Enzymol. 310, 131-144 (1999).
57. Webb JS, Givskov M, Kjelleberg S. Bacterial biofilms. prokaryotic adventures in multicellularity. Curr. Opin. Microbiol. 6(6), 578-585 (2003).
58. Krasovec R, Jerman I. Bacterial multicellularity as a possible source of antibiotic resistance. Med. Hypotheses 60(4), 484-488 (2003).
59. Ilyina TS, Romanova YM, Gintsburg AL. Biofilms as a mode of existence of bacteria in external environment and host body. The phenomenon, genetic control, and regulation systems of development. Russ. J. Genet. 40(11), 1189-1198 (2004).
60. Tanaka G, Shigeta M, Komatsuzawa H, Sugai M, Suginaka H, Usui T. Effect of the growth rate of Pseudomonas aeruginosa biofilms on the susceptibility to antimicrobial agents. b-lactams and fluoroquinolones. Chemotherapy 45(1), 28-36 (1999).
61. Ashby MJ, Neale JE, Knott SJ, Critchley IA. Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli. J. Antimicrob. Chemother. 33(3), 443-452 (1994).
62. Picioreanu C, Van Loosdrecht MCM, Heijnen JJ. Discrete-Differential modelling of biofilm structure. Water Sci. Technol. 39(7), 8 (1999).
63. Hao X, Heijnen JJ, Van Loosdrecht MCM. Sensitivity analysis of a biofilm model describing a one-stage completely autotrophic nitrogen removal (CANON) process. Biotechnol. Bioeng. 77(3), 266-277 (2002).
64. Park S, Bae W, Rittmann BE. Multi-species nitrifying biofilm model (MSNBM) including free ammonia and free nitrous acid inhibition and oxygen limitation. Biotechnol. Bioeng. 105(6), 1115-1130 (2010).
65. Chaudhry M, Beg S. A review on the mathematical modeling of biofilm processes. advances in fundamentals of biofilm modeling. Chem. Eng. Technol. 21(9), 701-710 (1998).
66. Nelson YM, Lion LW, Shuler ML, Ghiorse WC. Modeling oligotrophic biofilm formation and lead adsorption to biofilm components. Environ. Sci. Technol. 30(6), 2027-2035 (1996).
67. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms. A common cause of persistent infections. Science 284(5418), 1318-1322 (1999).
68. O'Toole GA, Pratt LA, Watnick PI, Newman DK, Weaver VB, Kolter R. Genetic approaches to study of biofilms. Methods Enzymol. 310, 91-109 (1999).
69. Pratt LA, Kolter R. Genetic analyses of bacterial biofilm formation. Curr. Opin. Microbiol. 2(6), 598-603 (1999).
70. Boles BR, Thoendel M, Roth AJ, Horswill AR. Identification of genes involved in polysaccharide-independent Staphylococcus aureus biofilm formation. PLoS ONE 5(4), e10146 (2010).
71. Chagneau C, Saier MH, Jr. Biofilm-Defective mutants of Bacillus subtilis. J. Mol. Microbiol. Biotechnol. 8(3), 177-188 (2004).
72. Kristich CJ, Nguyen VT, Le T, Barnes AMT, Grindle S, Dunny GM. Development and use of an efficient system for random mariner transposon mutagenesis to identify novel genetic determinants of biofilm formation in the core Enterococcus faecalis genome. Appl. Environ. Microbiol. 74(11), 3377-3386 (2008).
73. Li J, Wang N. Genome-wide mutagenesis of Xanthomonas axonopodis pv. citri reveals novel genetic determinants and regulation mechanisms of biofilm formation. PLoS ONE 6(7), e21804 (2011).
74. Quoc PHT, Genevaux P, Pajunen M et al. Isolation and characterization of biofilm formation-Defective mutants of Staphylococcus aureus. Infect. Immun. 75(3), 1079-1088 (2007).
75. Richard ML, Nobile CJ, Bruno VM, Mitchell AP. Candida albicans biofilm- defective mutants. Eukaryotic Cell 4(8), 1493-1502 (2005).
76. Yoshida A, Kuramitsu HK. Multiple Streptococcus mutans genes are involved in biofilm formation. Appl. Environ. Microbiol. 68(12), 6283-6291 (2002).
77. Beloin C, Ghigo J-M. Finding gene expression patterns in bacterial biofilms. Trends Microbiol. 13(1), 16-19 (2005).
78. Knobloch JK, Bartscht K, Sabottke A, Rohde H, Feucht HH, Mack D. Biofilm formation by Staphylococcus epidermidis depends on functional RsbU, an activator of the sigB operon: Differential activation mechanisms due to ethanol and salt stress. J. Bacteriol. 183(8), 2624-2633 (2001).
79. Campbell IM, Crozier DN, Pawagi AB, Buivids IA. In vitro response of Staphylococcus aureus from cystic fibrosis patients to combinations of linoleic and oleic acids added to nutrient medium. J. Clin. Microbiol. 18(2), 408-415 (1983).
80. Mack D, Siemssen N, Laufs R. Parallel induction by glucose of adherence and a polysaccharide antigen specific for plastic-Adherent Staphylococcus epidermidis: Evidence for functional relation to intercellular adhesion. Infect. Immun. 60(5), 2048-2057 (1992).
81. Gerke C, Kraft A, Sussmuth R, Schweitzer O, Gotz F. Characterization of the N-Acetylglucosaminyltransferase activity involved in the biosynthesis of the Staphylococcus epidermidis polysaccharide intercellular adhesin. J. Biol. Chem. 273(29), 18586-18593 (1998).
82. Rachid S, Ohlsen K, Witte W, Hacker J, Ziebuhr W. Effect of subinhibitory antibiotic concentrations on polysaccharide intercellular adhesin expression in biofilm-forming Staphylococcus epidermidis. Antimicrob. Agents Chemother. 44(12), 3357-3363 (2000).
83. Cramton SE, Ulrich M, Gotz F, Doring G. Anaerobic conditions induce expression of polysaccharide intercellular adhesin in Staphylococcus aureus and Staphylococcus epidermidis. Infect. Immun. 69(6), 4079-4085 (2001).
84. Deighton M, Borland R. Regulation of slime production in Staphylococcus epidermidis by iron limitation. Infect. Immun. 61(10), 4473-4479 (1993).
85. Elci S, Atmaca S, Gul K. Effect of iron limitation on the amount of slime produced by strains of Staphylococcus epidermidis. Cytobios 84(338-339), 141-146 (1995).
86. Evans E, Brown MR, Gilbert P. Iron chelator, exopolysaccharide and protease production in Staphylococcus epidermidis: A comparative study of the effects of specific growth rate in biofilm and planktonic culture. Microbiology 140(Pt 1), 153-157 (1994).
87. Rachid S, Ohlsen K, Wallner U, Hacker J, Hecker M, Ziebuhr W. Alternative transcription factor sigma(B) is involved in regulation of biofilm expression in a Staphylococcus aureus mucosal isolate. J. Bacteriol. 182(23), 6824-6826 (2000).
88. Rowley G, Spector M, Kormanec J, Roberts M. Pushing the envelope: Extracytoplasmic stress responses in bacterial pathogens. Nat. Rev. Microbiol. 4(5), 383-394 (2006).
89. Chaturongakul S, Raengpradub S, Wiedmann M, Boor KJ. Modulation of stress and virulence in Listeria monocytogenes. Trends Microbiol. 16(8), 388-396 (2008).
90. Sachdeva P, Misra R, Tyagi AK, Singh Y. The sigma factors of Mycobacterium tuberculosis: Regulation of the regulators. FEBS J. 277(3), 605-626 (2010).
91. Senn MM, Bischoff M, Von Eiff C, Berger-Bachi B. B activity in a Staphylococcus aureus hemB mutant. J. Bacteriol. 187(21), 7397-7406 (2005).
92. Gill SR, Fouts DE, Archer GL et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-Resistant Staphylococcus aureus strain and a biofilm-producing methicillin-Resistant Staphylococcus epidermidis strain. J. Bacteriol. 187(7), 2426-2438 (2005).
93. Stock AM, Robinson VL, Goudreau PN. Two-Component signal transduction. Annu. Rev. Biochem. 69, 183-215 (2000).
94. Li M, Villaruz AE, Vadyvaloo V, Sturdevant DE, Otto M. AI-2-Dependent gene regulation in Staphylococcus epidermidis. BMC Microbiol. 8, 4 (2008).
95. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu. Rev. Microbiol. 55, 165-199 (2001).
96. Jayaraman A, Wood TK. Bacterial quorum sensing: Signals, circuits, and implications for biofilms and disease. Annu. Rev. Biomed. Eng. 10, 145-167 (2008).
97. Sturme MH, Kleerebezem M, Nakayama J, Akkermans AD, Vaugha EE, De Vos WM. Cell to cell communication by autoinducing peptides in Gram-positive bacteria. Antonie Van Leeuwenhoek 81(1-4), 233-243 (2002).
98. Xavier KB, Bassler BL. LuxS quorum sensing: more than just a numbers game. Curr. Opin. Microbiol. 6(2), 191-197 (2003).
99. Chauhan N, Calderone R. Two-Component signal transduction proteins as potential drug targets in medically important fungi. Infect. Immun. 76(11), 4795-4803 (2008).
100. Raffa RB, Iannuzzo JR, Levine DR et al. Bacterial communication ("quorum sensing") via ligands and receptors. a novel pharmacologic target for the design of antibiotic drugs. J. Pharmacol. Exp. Ther. 312(2), 417-423 (2005).
101. Kleerebezem M, Quadri LE, Kuipers OP, De Vos WM. Quorum sensing by peptide pheromones and two-Component signal-Transduction systems in Gram-positive bacteria. Mol. Microbiol. 24(5), 895-904 (1997).
102. Gotoh Y, Eguchi Y, Watanabe T, Okamoto S, Doi A, Utsumi R. Two-Component signal transduction as potential drug targets in pathogenic bacteria. Curr. Opin. Microbiol. 13(2), 232-239 (2010).
103. Fuqua C, Parsek MR, Greenberg EP. Regulation of gene expression by cell-To-Cell communication: Acyl-homoserine lactone quorum sensing. Annu. Rev. Genet. 35, 439-468 (2001).
104. Taga ME, Bassler BL. Chemical communication among bacteria. Proc. Natl Acad. Sci. USA 100(Suppl. 2), 14549-14554 (2003).
105. Passador L, Tucker KD, Guertin KR, Journet MP, Kende AS, Iglewski BH. Functional analysis of the Pseudomonas aeruginosa autoinducer PAI. J. Bacteriol. 178(20), 5995-6000 (1996).
106. Schaefer AL, Hanzelka BL, Eberhard A, Greenberg EP. Quorum sensing in Vibrio fischeri: Probing autoinducer-LuxR interactions with autoinducer analogs. J. Bacteriol. 178(10), 2897-2901 (1996).
107. Rasko DA, Moreira CG, Li DR et al. Targeting QseC signaling and virulence for antibiotic development. Science 321(5892), 1078-1080 (2008).
108. Balaban N, Cirioni O, Giacometti A et al. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob. Agents Chemother. 51(6), 2226-2229 (2007).
109. Roy V, Smith JaI, Wang J, Stewart JE, Bentley WE, Sintim HO. Synthetic analogs tailor native AI-2 signaling across bacterial species. J. Am. Chem. Soc. 132(32), 11141-11150 (2010).
110. Roy V, Adams BL, Bentley WE. Developing next generation antimicrobials by intercepting AI-2 mediated quorum sensing. Enzyme Microb. Technol. 49(2), 113-123 (2011).
111. Rui F, Marques JC, Miller ST, Maycock CD, Xavier KB, Ventura MR. Stereochemical diversity of AI-2 analogs modulates quorum sensing in Vibrio harveyi and Escherichia coli. Bioorg. Med. Chem. 20(1), 249-256 (2012).
112. Tsuchikama K, Lowery CA, Janda KD. Probing autoinducer-2 based quorum sensing: The biological consequences of molecules unable to traverse equilibrium states. J. Org. Chem. 76(17), 6981-6989 (2011).
113. Lowery CA, Mckenzie KM, Qi L, Meijler MM, Janda KD. Quorum sensing in Vibrio harveyi: Probing the specificity of the LuxP binding site. Bioorg. Med. Chem. Lett. 15(9), 2395-2398 (2005).
114. Reo NV. NMR-Based metabolomics. Drug Chem Toxicol 25(4), 375-382 (2002).
115. Fiehn O. Metabolomics-The link between genotypes and phenotypes. Plant Mol. Biol. 48(1-2), 155-171 (2002).
116. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 16(9), 373-378 (1998).
117. Beckonert O, Keun HC, Ebbels TM et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2(11), 2692-2703 (2007).
118. Rubakhin SS, Romanova EV, Nemes P, Sweedler JV. Profiling metabolites and peptides in single cells. Nat. Methods. 8(4 Suppl.), S20-S29 (2011).
119. Roos V, Klemm P. Global gene expression profiling of the asymptomatic bacteriuria Escherichia coli strain 83972 in the human urinary tract. Infect. Immun. 74(6), 3565-3575 (2006).
120. Vilain S, Cosette P, Zimmerlin I, Dupont JP, Junter GA, Jouenne T. Biofilm proteome: Homogeneity or versatility? J. Proteome. Res. 3(1), 132-136 (2004).
121. Peregrin-Alvarez JM, Sanford C, Parkinson J. The conservation and evolutionary modularity of metabolism. GenomeBiol. 10(6), R63 (2009).
122. Monds RD, O'Toole GA. Metabolites as intercellular signals for regulation of community-level traits. In: Chemical Communication Among Bacteria. Winans SC, Bassler BL (Eds). ASM Press, Washington, DC, USA, 105-130 (2008).
123. Halouska S, Fenton RJ, Barletta RG, Powers R. Predicting the in vivo mechanism of action for drug leads using NMR metabolomics. ACS Chem. Biol. 7(1), 166-171 (2012).
124. Zhang B, Halouska S, Schiaffo CE, Sadykov MR, Somerville GA, Powers R. NMR analysis of a stress response metabolic signaling network. J. Proteome Res. 10(8), 3743-3754 (2011).
125. Shanaiah N, Zhang S, Desilva MA, Raftery D. NMR-Based metabolomics for biomarker discovery. In: Biomarker Methods in Drug Discovery and Development. Wang F (Ed.). Springer, NY, USA, 341-368 (2008).
126. Bino RJ, Hall RD, Fiehn O et al. Potential of metabolomics as a functional genomics tool. Trends Plant Sci. 9(9), 418-425 (2004).
127. Powers R. NMR metabolomics and drug discovery. Magn. Reson. Chem. 47(Suppl. 1), S2-S11 (2009).
128. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-Based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem. Res. Toxicol. 21(1), 9-27 (2008).
129. Vinaixa M, Angel RM, Rull A et al. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J. Proteome Res. 9(5), 2527-2538 (2010).
130. Griffin JL, Atherton H, Shockcor J, Atzori L. Metabolomics as a tool for cardiac research. Nat. Rev. Cardiol. 8(11), 630-643 (2011).
131. Li H, Wang L, Yan X et al. A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. J. Proteome Res. 10(6), 2797-2806 (2011).
132. Mcclay JL, Adkins DE, Isern NG et al. 1H Nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J. Proteome Res. 9(6), 3083-3090 (2010).
133. Sofia M, Maniscalco M, De LG, Paris D, Melck D, Motta A. Exploring airway diseases by NMR-Based metabonomics: A review of application to exhaled breath condensate. J. Biomed. Biotechnol. 2011(2011), 403260 (2011).
134. Macintyre DA, Jimenez B, Lewintre EJ et al. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia 24(4), 788-797 (2010).
135. Carrola J, Rocha CM, Barros AS et al. Metabolic signatures of lung cancer in biofluids. NMR-Based metabonomics of urine. J. Proteome Res. 10(1), 221-230 (2011).
136. Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by 1H nuclear magnetic resonance: Identification, mapping, and evolution. J. Proteome Res., 11(2), 1274-1283 (2012).
137. Bertini I, Cacciatore S, Jensen BV et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 72(1), 356-364 (2012).
138. Kork F, Holthues J, Hellweg R et al. A possible new diagnostic biomarker in early diagnosis of Alzheimer's disease. Curr. Alzheimer Res. 6(6), 519-524 (2009).
139. Sinclair AJ, Viant MR, Ball AK et al. NMR-Based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases-A diagnostic tool? NMR Biomed. 23(2), 123-132 (2010).
140. Blasco H, Corcia P, Moreau C et al. 1H-NMR-Based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS ONE 5(10), e13223 (2010).
141. Stoop MP, Coulier L, Rosenling T et al. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol. Cell. Proteomics 9(9), 2063-2075 (2010).
142. Tiziani S, Kang Y, Choi JS, Roberts W, Paternostro G. Metabolomic high-Content nuclear magnetic resonance-Based drug screening of a kinase inhibitor library. Nat. Commun. 2, 545 (2011).
143. Lindon JC, Keun HC, Ebbels TMD, Pearce JMT, Holmes E, Nicholson JK. The Consortium for Metabonomic Toxicology (COMET): Aims, activities and achievements. Pharmacogenomics 6(7), 691-699 (2005).
144. Robertson DG, Reily MD, Baker JD. Metabonomics in pharmaceutical discovery and development. J. Proteome Res. 6(2), 526-539 (2007).
145. Wishart DS. Applications of metabolomics in drug discovery and development. Drugs Res. Dev. 9(5), 307-322 (2008).
146. Fernie AR, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat. Rev. Mol. Cell Biol. 5(9), 763-769 (2004).
147. Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 8(9), 1243-1266 (2007).
148. Booth SC, Workentine ML, Wen J et al. Differences in metabolism between the biofilm and planktonic response to metal stress. J. Proteome Res. 10(7), 3190-3199 (2011).
149. Gjersing EL, Herberg JL, Horn J, Schaldach CM, Maxwell RS. NMR metabolomics of planktonic and biofilm modes of growth in Pseudomonas aeruginosa. Anal. Chem. 79(21), 8037-8045 (2007).
150. Zulak KG, Weljie AM, Vogel HJ, Facchini PJ. Quantitative 1H NMR metabolomics reveals extensive metabolic reprogramming of primary and secondary metabolism in elicitor-Treated opium poppy cell cultures. BMC Plant Biol. 8, 5 (2008
151. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin JL. High resolution 1H NMR-Based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J. Biol. Chem. 280(52), 42508-42514 (2005).
152. Sadykov MR, Zhang B, Halouska S et al. Using NMR metabolomics to investigate tricarboxylic acid cycle-Dependent signal transduction in Staphylococcus epidermidis. J. Biol. Chem. 285(47), 36616-36624 (2010).
153. Kjeldahl K, Bro R. Some common misunderstandings in chemometrics. J. Chemom. 24(7-8), 558-564 (2010).
154. Kumar A, Bhardwaj A. Methods in cell separation for biomedical application: Cryogels as a new tool. Biomed. Mater. 3(3), 034008 (2008).
155. Bolten CJ, Kiefer P, Letisse F, Portais JC, Wittmann C. Sampling for metabolome analysis of microorganisms. Anal. Chem. 79(10), 3843-3849 (2007).
156. Faijes M, Mars AE, Smid EJ. Comparison of quenching and extraction methodologies for metabolome analysis of Lactobacillus plantarum. Microb. Cell Fact. 6, 27 (2007).
157. Maharjan RP, Ferenci T. Global metabolite analysis: The influence of extraction methodology on metabolome profiles of Escherichia coli. Anal. Biochem. 313(1), 145-154 (2003).
158. Canelas A, Ras C, Ten Pierick A, Van Dam J, Heijnen J, Van Gulik W. Leakage-free rapid quenching technique for yeast metabolomics. Metabolomics 4(3), 226-239 (2008).
159. Wu XH, Yu HL, Ba ZY, Chen JY, Sun HG, Han BZ. Sampling methods for NMR-Based metabolomics of Staphylococcus aureus. Biotechnol. J. 5(1), 75-84 (2010).
160. Tredwell GD, Edwards-Jones B, Leak DJ, Bundy JG. The development of metabolomic sampling procedures for Pichia pastoris, and baseline metabolome data. PLoS ONE 6(1), e16286 (2011).
161. Rabinowitz JD. Cellular metabolomics of Escherchia coli. Expert Rev. Proteomics 4(2), 187-198 (2007).
162. Shaw L, Golonka E, Potempa J, Foster SJ. The role and regulation of the extracellular proteases of Staphylococcus aureus. Microbiology 150(Pt 1), 217-228 (2004).
163. Wittmann C, Kromer JO, Kiefer P, Binz T, Heinzle E. Impact of the cold shock phenomenon on quantification of intracellular metabolites in bacteria. Anal. Biochem. 327(1), 135-139 (2004).
164. Weckwerth W, Wenzel K, Fiehn O. Process for the integrated extraction, identification and quantification of metabolites, proteins and RNA to reveal their co-Regulation in biochemical networks. Proteomics 4(1), 78-83 (2004).
165. Wu H, Southam AD, Hines A, Viant MR. High-Throughput tissue extraction protocol for NMR- And MS-Based metabolomics. Anal. Biochem. 372(2), 204-212 (2008).
166. Bennett BD, Kimball EH, Gao M, Osterhout R, Van Dien SJ, Rabinowitz JD. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol. 5(8), 593-599 (2009).
167. Kell DB. Metabolomics and systems biology: making sense of the soup. Curr. Opin. Microbiol. 7(3), 296-307 (2004).
168. Blow N. Metabolomics: Biochemistry's new look. Nature 455(7213), 697-700 (2008).
169. Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. HPLC-MS-Based methods for the study of metabonomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 817(1), 67-76 (2005).
170. Freeman R. Magnetic Resonance in Chemistry and Medicine. Oxford University Press, London, UK (2003).
171. Moskau D, Ritcher C, Kovaks H et al. Highest sensitivity for cutting-Edge NMR applications. 600 MHz CryoProbes. Spectra Analyse 32(231), 39-41 (2003).
172. Keun HC, Beckonert O, Griffin JL et al. Cryogenic probe 13C NMR spectroscopy of urine for metabonomic studies. Anal. Chem. 74(17), 4588-4593 (2002).
173. Carrieri D, Mcneely K, De Roo AC, Bennette N, Pelczer I, Dismukes GC. Identification and quantification of water-soluble metabolites by cryoprobe-Assisted nuclear magnetic resonance spectroscopy applied to microbial fermentation. Magn. Reson. Chem. 47(S1), S138-S146 (2009).
174. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Analyt. Bioanal. Chem. 387(2), 525-527 (2007).
175. Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS. Quantitative metabolomics by 1H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS ONE 5(5), e10538 (2010).
176. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem. 387(2), 525-527 (2007).
177. Gu H, Pan Z, Xi B, Asiago V, Musselman B, Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: Application to the detection of breast cancer. Anal. Chim. Acta 686(1-2), 57-63 (2011).
178. Atherton HJ, Bailey NJ, Zhang W et al. A combined 1H-NMR spectroscopy- And mass spectrometry-Based metabolomic study of the PPAR-A null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol. Genomics 27(2), 178-186 (2006).
179. Wang H, Manicke NE, Yang Q et al. Direct analysis of biological tissue by paper spray mass spectrometry. Anal. Chem. 83(4), 1197-1201 (2011).
180. Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM. Targeted profiling: Quantitative analysis of 1H NMR metabolomics data. Anal. Chem. 78(13), 4430-4442 (2006).
181. Moestue S, Sitter B, Bathen TF, Tessem M-B, GribbestadIS. HR MAS MR spectroscopy in metabolic characterization of cancer. Curr. Top. Med. Chem. 11(1), 2-26 (2011).
182. Sitter B, Bathen TF, Singstad TE et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 23(4), 424-431 (2010).
183. Li M, Song Y, Cho N et al. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS ONE 6(10), e25563 (2011).
184. Portais JC, Delort AM. Carbohydrate cycling in micro-organisms: What can (13)C-NMR tell us? FEMS Microbiol. Rev. 26(4), 375-402 (2002).
185. Zamboni N, Sauer U. Novel biological insights through metabolomics and 13C-flux analysis. Curr. Opin. Microbiol. 12(5), 553-558 (2009).
186. Desilva MA, Shanaiah N, Nagana Gowda GA, Rosa-Perez K, Hanson BA, Raftery D. Application of 31P NMR spectroscopy and chemical derivatization for metabolite profiling of lipophilic compounds in human serum. Magn. Reson. Chem. 47(Suppl. 1), S74-S80 (2009).
187. Meiboom S, Gill D. Modified spin-Echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 29(8), 4 (1958).
188. Kaiser KA, Barding GA, Jr, Larive CK. A comparison of metabolite extraction strategies for 1H-NMR-Based metabolic profiling using mature leaf tissue from the model plant Arabidopsis thaliana. Magn. Reson. Chem. 47(Suppl. 1), S147-S156 (2009).
189. Martineau E, Tea I, Loaec G, Giraudeau P, Akoka S. Strategy for choosing extraction procedures for NMR-Based metabolomic analysis of mammalian cells. Anal. Bioanal. Chem. 401(7), 2133-2142 (2011
190. William S. Water signal suppression in NMR spectroscopy. In: Annual Reports on NMR Spectroscopy. Webb GA (Ed.). Academic Press, Boston, MA, USA, 289-354 (1999).
191. Beckonert O, Coen M, Keun HC et al. High-Resolution magic-Angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 5(6), 1019-1032 (2010).
192. Cloarec O, Dumas M-E, Craig A et al. Statistical total correlation spectroscopy. an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal. Chem. 77(5), 1282-1289 (2005).
193. Crockford DJ, Holmes E, Lindon JC et al. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets. application in metabonomic toxicology studies. Anal. Chem. 78(2), 363-371 (2005).
194. Xi Y, De Ropp J, Viant M, Woodruff D, Yu P. Automated screening for metabolites in complex mixtures using 2D COSY NMR spectroscopy. Metabolomics 2(4), 221-233 (2006).
195. Ludwig C, Ward DG, Martin A et al. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn. Reson. Chem. 47(Suppl. 1), S68-S73 (2009).
196. Ludwig C, Viant MR. Two-Dimensional J-Resolved NMR spectroscopy: Review of a key methodology in the metabolomics toolbox. Phytochem. Anal. 21(1), 22-32 (2010).
197. Aue WP, Karhan J, Ernst RR. Homonuclear broad band decoupling and two-Dimensional J-Resolved NMR spectroscopy. J. Chem. Phys. 64(10), 4226-4227 (1976).
198. Fonville JM, Maher AD, Coen M, Holmes E, Lindon JC, Nicholson JK. Evaluation of full-Resolution J-Resolved 1H NMR projections of biofluids for metabonomics information retrieval and biomarker identification. Anal. Chem. 82(5), 1811-1821 (2010).
199. Palmer AI, Cavanagh J, Wright P, Rance M. Sensitivity improvement in proton-Detected two-Dimensional heteronuclear correlation NMR spectroscopy. J. Magn. Reson. 93(1), 151-170 (1991).
200. Peyrauda R, Kiefera P, Christena P, Massoub S, Portaisb J, Vorholta J. Demonstration of the ethylmalonyl-CoA pathway by using 13C metabolomics. Proc. Natl Acad. Sci. USA 106(12), 4846-4851 (2009).
201. Jans AW, Willem R. 13C-NMR study of glycerol metabolism in rabbit renal cells of proximal convoluted tubules. Eur. J. Biochem. 174(1), 67-73 (1988).
202. Sadykov MR, Zhang B, Halouska S et al. Using NMR metabolomics to investigate tricarboxylic acid cycle dependent signal transduction in Staphylococcus epidermidis. J. Biol. Chem. 285(47), 36616-36624 (2010).
203. Shanaiah N, Desilva MA, Nagana Gowda GA, Raftery MA, Hainline BE, Raftery D. Class selection of amino acid metabolites in body fluids using chemical derivatization and their enhanced 13C NMR. Proc. Natl Acad. Sci. USA 104(28), 11540-11544 (2007).
204. Hu K, Westler WM, Markley JL. Simultaneous quantification and identification of individual chemicals in metabolite mixtures by two-Dimensional extrapolated time-zero 1H-13C HSQC (HSQC0). J. Am. Chem. Soc. 133(6), 1662-1665 (2011).
205. Holmes E, Foxall PJD, Nicholson JK et al. Automatic data reduction and pattern recognition methods for analysis of 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Anal. Biochem. 220(2), 284-296 (1994).
206. Ross A, Schlotterbeck G, Klaus W, Senn H. Automation of NMR measurements and data evaluation for systematically screening interactions of small molecules with target proteins. J. Biomol. NMR 16(2), 139-146 (2000).
207. Anderson PE, Reo NV, Delraso NJ, Doom TE, Raymer ML. Gaussian binning: A new kernel-Based method for processing NMR spectroscopic data for metabolomics. Metabolomics 4(3), 261-272 (2008).
208. Davis RA, Charlton AJ, Godward J, Jones SA, Harrison M, Wilson JC. Adaptive binning: An improved binning method for metabolomics data using the undecimated wavelet transform. Chemom. Intell. Lab. Syst. 85(1), 144-154 (2007).
209. De Meyer T, Sinnaeve D, Van Gasse B et al. NMR-Based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal. Chem. 80(10), 3783-3790 (2008).
210. Anderson PE, Mahle DA, Doom TE, Reo NV, Del RNJ, Raymer ML. Dynamic adaptive binning: An improved quantification technique for NMR spectroscopic data. Metabolomics 7(2), 179-190 (2011).
211. Halouska S, Powers R. Negative impact of noise on the principal component analysis of NMR data. J. Magn. Reson. 178(1), 88-95 (2006).
212. Wu W, Daszykowski M, Walczak B et al. Peak alignment of urine NMR spectra using fuzzy warping. J. Chem. Inf. Model. 46(2), 863-875 (2006).
213. Forshed J, Schuppe-Koistinen I, Jacobsson SP. Peak alignment of NMR signals by means of a genetic algorithm. Anal. Chim. Acta 487(2), 189-199 (2003).
214. Veselkov KA, Lindon JC, Ebbels TMD et al. Recursive Segment-wise peak alignment of biological 1H NMR spectra for improved metabolic biomarker recovery. Anal. Chem. 81(1), 56-66 (2009).
215. Csenki L, Alm E, Torgrip RJO et al. Proof of principle of a generalized fuzzy Hough transform approach to peak alignment of one-Dimensional 1H NMR data. Anal. Bioanal. Chem. 389(3), 875-885 (2007).
216. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal. Chem. 78(7), 2262-2267 (2006).
217. De Meyer T, Sinnaeve D, Van Gasse B et al. Evaluation of standard and advanced preprocessing methods for the univariate analysis of blood serum 1H-NMR spectra. Anal. Bioanal. Chem. 398(4), 1781-1790 (2010).
218. Oliver F. Cellular metabolimics: The quest for pathway structure. In: The Handbook of Metabonomics and Metabolomics. Lindon JC, Nicholson, JK, Holmes E (Eds). Elsevier Science, Amsterdam, The Netherlands, 20 (2007).
219. Lindon JC, Nicholson JK, Holmes E. The Handbook of Metabonomics and Metabolomics (1st Edition). Elsevier, Amsterdam, The Netherlands (2007).
220. Basant A, Rege M, Sharma S, Sonawat HM. Alterations in urine, serum and brain metabolomic profiles exhibit sexual dimorphism during malaria disease progression. Malaria J. 9(1), 110 (2010).
221. Westerhuis JA, Hoefsloot HCJ, Smit S et al. Assessment of PLSDA cross validation. Metabolomics 4(1), 81-89 (2008).
222. Rubingh CM, Bijlsma S, Derks EPPA et al. Assessing the performance of statistical validation tools for megavariate metabolomics data. Metabolomics 2(2), 53-61 (2006).
223. Keun HC, Ebbels TM, Antti H et al. Analytical reproducibility in (1)H NMR-Based metabonomic urinalysis. Chem. Res. Toxicol. 15(11), 1380-1386 (2002).
224. Wang T, Shao K, Chu Q et al. Automics. An integrated platform for NMR-Based metabonomics spectral processing and data analysis. BMC Bioinform. 10, 83 (2009).
225. Zhao Q, Stoyanova R, Du S, Sajda P, Brown TR. HiRes-A tool for comprehensive assessment and interpretation of metabolomic data. Bioinformatics 22(20), 2562-2564 (2006).
226. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: A web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 37, W652-W660 (2009
227. Izquierdo-Garcia J, Rodriguez I, Kyriazis A et al. A novel R-package graphic user interface for the analysis of metabonomic profiles. BMC Bioinf. 10(1), 363 (2009).
228. Werth MT, Halouska S, Shortridge MD, Zhang B, Powers R. Analysis of metabolomic PCA data using tree diagrams. Anal. Biochem. 399(1), 58-63 (2010).
229. Efron B, Halloran E, Holmes S. Bootstrap confidence levels for phylogenetic trees. Proc. Natl Acad. Sci. USA 93(14), 13429-13434 (1996).
230. Retief JD. Phylogenetic analysis using PHYLIP. Methods Mol. Biol. 132(2), 16 (1999).
231. Shulaev V. Metabolomics technology and bioinformatics. Briefings Bioinf. 7(2), 128-139 (2006).
232. Oberhardt MA, Palsson BO, Papin JA. Applications of genome-scale metabolic reconstructions. Mol. Syst. Biol. 5, 320 (2009).
233. Robinette SL, Ajredini R, Rasheed H et al. Hierarchical alignment and full resolution pattern recognition of 2D NMR spectra. Application to nematode chemical ecology. Anal. Chem. 83(5), 1649-1657 (2011).
234. Vu TN, Valkenborg D, Smets K et al. An integrated workflow for robust alignment and simplified quantitative analysis of NMR spectrometry data. BMC Bioinf. 12, 405 (2011).
235. Mo H, Raftery D. Solvent signal as an NMR concentration reference. Anal. Chem. 80(24), 9835-9839 (2008).
236. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal. Chem. 78(7), 2262-2267 (2006).
237. Xia J, Bjorndahl TC, Tang P, Wishart DS. MetaboMiner-semi-Automated identification of metabolites from 2D NMR spectra of complex biofluids. BMC Bioinf. 9, 507 (2008).
238. Cui Q, Lewis IA, Hegeman AD et al. Metabolite identification via the Madison Metabolomics Consortium Database. Nat. Biotechnol. 26(2), 162-164 (2008).
239. Ulrich EL, Akutsu H, Doreleijers JF et al. BioMagResBank. Nucleic Acids Res. 36, D402-D408 (2008).
240. Wishart DS, Knox C, Guo AC et al. HMDB. a knowledge-Base for the human metabolome. Nucleic Acids Res. 37, D603-D610 (2009).
241. Kanehisa M, Araki M, Goto S et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 36, D480-D484 (2008).
242. Caspi R, Foerster H, Fulcher CA et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 36, D623-D631 (2008).
243. Cline MS, Smoot M, Cerami E et al. Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2(10), 2366-2382 (2007).
244. Viswanathan GA, Seto J, Patil S, Nudelman G, Sealfon SC. Getting started in biological pathway construction and analysis. PLoS Comput. Biol. 4(2), e16 (2008).
245. Funahashi A, Jouraku A, Matsuoka Y, Kitano H. Integration of CellDesigner and SABIO-RK. In Silico Biol. 7(Suppl. 2), S81-S90 (2007).
246. Workentine ML, Harrison JJ, Weljie AM et al. Phenotypic and metabolic profiling of colony morphology variants evolved from Pseudomonas fluorescens biofilms. Environ. Microbiol. 12(6), 1565-1577 (2010).
247. Hall-Stoodley L, Hu FZ, Gieseke A et al. Direct detection of bacterial biofilms on the middle-Ear mucosa of children with chronic otitis media. J. Am. Med. Assoc. 296(2), 202-211 (2006).
248. Kim YH, An ES, Song BK, Kim DS, Chelikani R. Polymerization of cardanol using soybean peroxidase and its potential application as anti-Biofilm coating material. Biotechnol. Lett. 25(18), 1521-1524 (2003).
249. Carlson RP, Taffs R, Davison WM, Stewart PS. Anti-Biofilm properties of chitosan-Coated surfaces. J. Biomater. Sci. Polym. Ed. 19(8), 1035-1046 (2008).
250. Khoo X, Grinstaff MW. Novel infection-Resistant surface coatings: A bioengineering approach. MRS Bull. 36(5), 357-366 (2011).
251. Shunmugaperumal T. Microbial colonization of medical devices and novel preventive strategies. Recent Pat. Drug Deliv. Formul. 4(2), 153-173 (2010).
252. Vogt M, Flemming HC, Veeman WS. Diffusion in Pseudomonas aeruginosa biofilms: A pulsed field gradient NMR study. J. Biotechnol. 77(1), 137-146 (2000).
253. Hoyle BD, Alcantara J, Costerton JW. Pseudomonas aeruginosa biofilm as a diffusion barrier to piperacillin. Antimicrob. Agents Chemother. 36(9), 2054-2056 (1992).
254. Rogers SA, Huigens RW 3rd, Cavanagh J, Melander C. Synergistic effects between conventional antibiotics and 2-Aminoimidazole-Derived antibiofilm agents. Antimicrob. Agents Chemother. 54(5), 2112-2118 (2010).
255. Walencka E, Rozalska S, Wysokinska H, Rozalski M, Kuzma L, Rozalska B. Salvipisone and aethiopinone from Salvia sclarea hairy roots modulate staphylococcal antibiotic resistance and express anti-Biofilm activity. Planta Med. 73(6), 545-551 (2007).
256. Sadykov MR, Olson ME, Halouska S et al. Tricarboxylic acid cycle dependent regulation of Staphylococcus epidermidis polysaccharide intercellular adhesin synthesis. J. Bacteriol. 130(23), 7621-7632 (2008).
257. White AP, Weljie AM, Apel D et al. A global metabolic shift is linked to Salmonella multicellular development. PLoS ONE 5(7), e11814 (2010).
258. Theodore TS, Schade AL. Carbohydrate metabolism of iron-Rich and iron-poor Staphylococcus aureus. J. Gen. Microbiol. 40(3), 385-395 (1965).
259. Musk DJ Jr, Hergenrother PJ. Chelated iron sources are inhibitors of Pseudomonas aeruginosa biofilms and distribute efficiently in an in vitro model of drug delivery to the human lung. J. Appl. Microbiol. 105(2), 380-388 (2008).
260. Moreau-Marquis S, O'Toole GA, Stanton BA. Tobramycin and FDA-Approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am. J. Respir. Cell Mol. Biol. 41(3), 305-313 (2009).
261. Liebeke M, Dorries K, Zuhlke D et al. A metabolomics and proteomics study of the adaptation of Staphylococcus aureus to glucose starvation. Mol. Biosyst. 7(4), 1241-1253 (2011).
262. Persidis A. High-Throughput screening. Nat. Biotechnol. 16(5), 488-489 (1998).
263. Sittampalam GS, Kahl SD, Janzen WP. High-Throughput screening: Advances in assay technologies. Curr. Opin. Cell Biol. 1(3), 384-391 (1997).
264. Bordi C, De Bentzmann S. Hacking into bacterial biofilms: A new therapeutic challenge. Ann. Intensive Care 1(1), 1-8 (2011).
265. Roy V, Smith JA, Wang J, Stewart JE, Bentley WE, Sintim HO. Synthetic analogs tailor native AI-2 signaling across bacterial species. J. Am. Chem. Soc. 132(32), 11141-11150 (2010).
266. Rui F, Marques JC, Miller ST, Maycock CD, Xavier KB, Ventura MR. Stereochemical diversity of AI-2 analogs modulates quorum sensing in Vibrio harveyi and Escherichia coli. Bioorg. Med. Chem. 20(1), 249-256 (2012).
267. Forgue P, Halouska S, Werth M, Xu K, Harris S, Powers R. NMR Metabolic profiling of Aspergillus nidulans to Monitor drug and protein activity. J. Proteome Res. 5(8), 1916-1923 (2006).
268. Teng Q, Huang W, Collette TW, Ekman DR, Tan C. A direct cell quenching method for cell-Culture based metabolomics. Metabolomics 5(2), 199-208 (2009).
269. Fogh RH, Vranken WF, Boucher W, Stevens TJ, Laue ED. A nomenclature and data model to describe NMR experiments. J. Biomol. NMR 36(3), 147-155 (2006).
270. Pons JL, Malliavin TE, Delsuc MA. Gifa V. A complete package for NMR data set processing. J. Biomol. NMR 8(4), 445-452 (1996).
271. Van Beek JD. matNMR: A flexible toolbox for processing, analyzing and visualizing magnetic resonance data in Matlab. J. Magn. Reson. 187(1), 19-26 (2007).
272. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRpipe: A multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6(3), 277-293 (1995).
273. Lewis IA, Schommer SC, Markley JL. rNMR: Open source software for identifying and quantifying metabolites in NMR spectra. Magn. Reson. Chem. 47(Suppl. 1), S123-S126 (2009).
274. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo (1)H magnetic resonance spectroscopy data. Magn. Reson. Med. 65(1), 1-12 (2011)